May 8 2015
MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Center for Integrated Oncology at Cologne University Hospital, headed by Prof. Dr. med. Roland Goldbrunner, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers in addition to the ongoing post-marketing study.
This represents the inauguration of the third clinic in Germany that offers the benefit of MagForce's NanoTherm(TM) therapy for brain cancer patients in addition to the University Hospitals in Münster and Kiel.
"With Cologne we have established another renowned medical center for treating brain cancer patients with our proprietary NanoTherm(TM) therapy also in the commercial setting. This expansion provides more geographic opportunites for treatment within Germany. We are very happy to see increasing interest by private pay patients and also with the successful interaction with the key opinion leaders in the medical community," commented Dr. Ben J. Lipps, CEO of MagForce AG and MagForce USA, Inc.
Additional to the increasing commercial business in Europe, the key focus of MagForce is on the US market.
MagForce - German, stock market listed healthcare company using nanotechnology for cancer treatment
"We continue to be on track with our preparations for the approval process in the U.S. for both brain and prostate cancer," Dr. Ben J. Lipps added.
Source: http://www.magforce.com/